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Abstract
Asthma is prevalent in athletes and when untreated can impact both respiratory health and sports performance. Pharmaco-
logical inhaler therapy currently forms the mainstay of treatment; however, for elite athletes competing under the constraints 
of the World Anti-Doping Code (Code), a number of established therapies are prohibited both in and/or out of competition 
and/or have a maximum permitted dose. The recent release of medical information detailing inhaler therapy in high-profile 
athletes has brought the legitimacy and utilisation of asthma medication in this setting into sharp focus. This narrative review 
critically appraises recent changes to anti-doping policy and the Code in the context of asthma management, evaluates the 
impact of asthma medication use on sports performance and employs a theory of behaviour to examine perceived determi-
nants and barriers to athletes adhering to the anti-doping rules of sport when applied to asthma.
Key Points 
The perception that asthma medication may enhance 
sports performance has created a negative stigma 
towards athletes with asthma, inhaler therapy and thera-
peutic use exemptions (TUEs).
The capability, opportunity, motivation—behaviour 
(COM-B) model is a theoretical starting point to 
understanding behaviour in this setting and provides 
foundations for intervention development (e.g. education 
programmes and environmental restructuring).
Future developments in policy and practice have the 
potential to change behaviour, establish trust in the 
anti-doping system, and in turn, alter the attitudes and 
perceptions of asthma medication use in sport.
1 Introduction
Asthma is frequently reported as the most common medical 
condition in elite-level athletes [1–3], with recent studies 
indicating a prevalence of 25–75% in susceptible cohorts 
[4–6]. The reason for the heightened incidence in elite sport 
remains to be fully established; however, there is now evi-
dence indicating that airways hyper-reactivity can develop 
over the course of a sporting career (for review see Price 
et al. [7]). Beyond the elite athlete population, an increased 
frequency of asthma has also recently been reported in UK-
based recreational athletes (~ 15%) when compared with the 
general population [8].
For the most part, the treatment of asthma and/or exer-
cise-induced bronchoconstriction (EIB) in athletes is well 
established, with the recommendation that a short-acting 
β-2 agonist (SABA) (e.g. salbutamol) forms the mainstay 
of pharmacological therapy [9, 10]. However, for athletes 
competing under the constraints of the World Anti-Doping 
Code (Code), the use of SABA and several other commonly 
prescribed asthma medications puts athletes at risk of return-
ing an adverse analytical finding (AAF), potentially leading 
to an anti-doping rule violation (ADRV) and a period of 
ineligibility from sport [11]. Prior to initiating treatment, it 
is therefore imperative that athletes and their support person-
nel (e.g. sports physicians) have a thorough understanding 
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of the Code and the annually updated World Anti-Doping 
Agency (WADA) prohibited list [12].
In keeping with their non-athletic counterparts, elite ath-
letes with asthma are also susceptible to acute illness (e.g. 
respiratory tract infection) or ‘exacerbations’ that often 
require additional pharmacological therapy, which may be 
prohibited in competition, to restore and optimise health 
[13]. To ensure health protection is afforded for athletes 
bound by anti-doping rules and regulations, the Interna-
tional Olympic Committee—Medical Commission (IOC-
MC) introduced a policy in the 1980s for permitted use of 
prohibited substances and methods [14]. Currently, athletes 
competing at the elite level are thus typically required to 
provide objective evidence of asthma before a therapeutic 
use exemption (TUE) may be granted to permit use of an 
otherwise prohibited substance or medication dose.
The process to obtain a TUE was originally formalised 
following the introduction of the International Standard for 
Therapeutic Use Exemptions [15]. However, the legitimacy 
and utilisation of asthma medication use in this setting has 
been questioned for some time and highlighted in recent 
years following the release of personal medical information 
of several high-profile athletes by Russian cyber-espionage 
group Fancy Bears. For many this has served to reinforce 
perceptions of wrong-doing within the athlete community 
[16] and may prompt the misuse of asthma medication 
amongst those potentially seeking to gain an advantage.
Whilst instinctively, a decision to comply with the Code 
may be viewed as straightforward, factors underpinning 
non-compliance are often complex and have recently been 
conceptualised in the scope of a model evaluating the multi-
faceted dopogenic environment [17]. In this model, it is pro-
posed that an athlete may be influenced by the surroundings, 
opportunities and conditions that promote ADRVs. To fully 
understand the drivers of the misuse of asthma medication 
in sport, an appraisal of current literature guided by a con-
temporary and overarching model of behavioural theory 
(the capability, opportunity, motivation—behaviour [COM-
B] model) [18] is required. Drawing upon this model, it is 
proposed that behaviour (B) is the result of an interaction 
between three necessary conditions: capability, opportunity 
and motivation. For an individual to engage in a specific 
behaviour (B) they must have the psychological and physical 
capability (C) (e.g. knowledge), the social (e.g. peers) and 
physical opportunity (O) (e.g. resources), and the motivation 
(M) to undertake the behaviour. Motivation covers automatic 
processes, such as habit and impulses, as well as reflective 
processes, such as intention and choice [18].
This narrative review critically appraises recent changes 
to anti-doping policy and the Code in the context of asthma 
management, evaluates the impact of asthma medication use 
on sports performance, and employs a theory of behaviour 
(COM-B) to examine perceived determinants and barriers 
to athletes adhering to the anti-doping rules of sport when 
applied to asthma. In order to achieve these objectives, 
publications in the peer-reviewed literature from January 
2004 (conception of the Code) until December 2018 were 
reviewed using search terms such as ‘asthma’, ‘exercise-
induced asthma or bronchoconstriction’ in combination 
with ‘athletes’, ‘anti-doping’, ‘medication’ and ‘sports 
performance’.
2  The World Anti‑Doping Code
WADA was established in 1999 to harmonise global anti-
doping policy and practice. Most countries, and almost all 
sports, are signatories to the Code, with the major excep-
tions being North American professional sporting bodies 
(e.g. Major League Baseball). First published in January 
2004 [19], the Code provides the framework for anti-dop-
ing polices, rules and regulations within sport organisations 
and among public authorities. Along with five international 
standards (e.g. International Standard for Therapeutic Use 
Exemptions; List of Prohibited Substances and Methods), 
the Code serves to ensure that anti-doping policies and pro-
cedures are the same for all athletes and support personnel. 
Updated annually, the prohibited list contains substances and 
methods that if detected in the absence of a TUE, will result 
in an ADRV. The International Standard for Therapeutic Use 
Exemptions states that an athlete will only be granted a TUE 
if the following conditions are met: (a) the athlete would 
experience significant health impairment if the prohibited 
substance or method were to be withheld, (b) therapeutic use 
of the prohibited substance or method is unlikely to produce 
any additional performance enhancement, (c) there is no rea-
sonable therapeutic alternative to the use of the prohibited 
substance or method, and (d) the necessity for the use of the 
prohibited substance or method is not a consequence of the 
prior use (without a TUE) of a substance or method that was 
prohibited at the time of use [15].
2.1  The Code and Asthma
Following the conception of the Code in 2004, all inhaled 
β-2 agonists were prohibited without an abbreviated TUE 
(i.e. written medical notification) submitted to authorise 
the use of inhaled SABA (i.e. salbutamol and terbutaline), 
inhaled long-acting β-2 agonists (LABA) (i.e. formoterol 
and salmeterol) and inhaled corticosteroids [19]. Due to 
concerns over unnecessary β-2 agonist use in elite sport 
[20], the prohibited list was updated in 2009 resulting in all 
forms of β-2 agonists prohibited without an authorised TUE 
[21]. Since this point, athletes have been required to pro-
vide comprehensive medical history with supporting objec-
tive evidence of asthma via bronchodilator reversibility or 
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bronchoprovocation challenge testing to obtain a TUE [22] 
(summarised for reference in Table 1).
Permitted limits were introduced for inhaled salbutamol, 
salmeterol and formoterol between 2010 and 2012. The 
requisite to submit a TUE during this period was therefore 
no longer required for these substances (unless an athlete 
exceeded permitted limits in a medical emergency whereby 
a retroactive TUE was still required) [23]. The decision to 
implement threshold values was made to remove the admin-
istrative burden of TUE approval, and coincided with lim-
ited evidence concerning performance-enhancing properties 
associated with inhaled β-2 agonist therapy [24]. Following 
these modifications, in 2013, the maximum permitted dose 
for inhaled formoterol was updated to 54 µg over 24 h [25] 
and, 4 years later, the maximum permitted dose for inhaled 
salbutamol and inhaled salmeterol, over a 24-h period, was 
updated to 1600 µg (not exceeding 800 µg per 12 h) and 
200 µg, respectively [26].
The current prohibited list (summarised for reference 
in Table 2) states that athletes are permitted to adminis-
ter inhaled salbutamol (in divided doses not exceeding 
1600 µg in 24 h and 800 µg in 12 h), formoterol (≤ 54 µg 
in 24 h) and salmeterol (≤ 200 µg in 24 h) [12] without 
a TUE. Salbutamol and formoterol are associated with 
permitted urine thresholds of 1000 ng/mL and 40 ng/mL, 
and decision limits (accounting for measurement uncer-
tainty) of 1200 ng/mL and 50 ng/mL, respectively [27]. 
An athlete found to exceed the urinary decision limit for a 
substance may request an individualised pharmacokinetic 
study. Indeed, following recent high-profile anti-doping 
investigations concerning asthma medication use in elite 
athletes, a pharmacokinetic modelling study demon-
strated that an AAF for salbutamol has the potential to 
occur irrespective of adherence to current guidelines (i.e. 
doses administered below or within upper limits) [28]. To 
date, a urine threshold for salmeterol  has not been imple-
mented despite evidence concerning the ability to detect 
following inhalation [29]. Similarly, although differences 
in urinary concentrations between oral and inhaled terb-
utaline have been demonstrated, a threshold has yet to be 
established [30]. The current clinical practice guideline 
statement concerning the management of EIB in athletes 
recommends inhaled SABA—15 min prior to commenc-
ing exercise—as the most effective approach to managing 
troublesome respiratory symptoms [9]. However, in the 
context of elite sport, athletes typically complete multi-
ple exercise bouts or training sessions per day. To avoid 
overuse and potential adverse effects, or reduced tolerance 
and efficacy of reliever medication [31], it is recommended 
that daily inhaled corticosteroid maintenance therapy is 
initiated to target underlying airway inflammation and 
optimise asthma management [9]. Inhaled corticosteroids 
remain permitted in and out of competition without a TUE 
[12]. However, the systemic administration of corticos-
teroids (i.e. oral route most commonly), that may be used 
to treat severe acute asthma exacerbations [13] requires 
a TUE for use in competition but is not prohibited out of 
competition [12].
It is important to acknowledge that any responsible cli-
nician should ensure that the care afforded to an athlete 
with asthma is always prioritised. In the event a prohibited 
substance is administered to treat an asthma exacerbation, 
the athlete is required to apply for a retroactive TUE [15]. 
A retroactive TUE may also be sought by drug-tested 
athletes who are not deemed to be International Level or 
National Level if a doping control test returns an AAF 
[11]. In this scenario, guidance provided by WADA to 
clinicians emphasises the need for “full and clear docu-
mentation of the medical incident” [22].
Table 1  Objective testing 
accepted by the World Anti-
Doping Agency to diagnose 
asthma in athletes
FEV1 forced expiratory volume in one second, IOC-MC International Olympic Committee—Medical Com-
mission
a Supports asthma diagnosis
b Optimal test to detect asthma in athletes (IOC-MC)
c Sustained reduction in  FEV1 required (i.e. two consecutive timepoints) to confirm diagnosis
Diagnostic methods Criteria
Bronchodilator reversibility ≥ 12% increase in  FEV1a
Bronchoprovocation challenge(s):
 Direct
  Methacholine/histamine ≥ 20% reduction in  FEV1
 Indirect
  Exercise challenge (laboratory and field-based) ≥ 10% reduction in  FEV1c
  Eucapnic voluntary hyperpnoea (EVH)b ≥ 10% reduction in  FEV1c
  Dry powder mannitol ≥ 15% reduction in  FEV1
  Hypertonic saline (4.5%) ≥ 15% reduction in  FEV1
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3  Impact of Medication on Sports 
Performance
The impact of asthma and associated treatment on athletic 
performance has been extensively investigated (for review 
see Price et al. [32]). Yet, despite several proposed physi-
ological mechanisms indicating asthma may impair sporting 
performance, there remains limited experimental evidence 
to support or refute this concept. Indeed, elite-level athletes 
with asthma are consistently reported to match and indeed in 
some cases out-perform their non-asthmatic rivals [1], fuel-
ling widespread speculation concerning the performance-
enhancing properties of asthma therapy [33].
3.1  Inhaled β‑2 Agonists and Corticosteroids Not 
Requiring a Therapeutic Use Exemption (TUE)
A great number of studies have been undertaken evaluating 
the impact of inhaled salbutamol on exercise performance 
with no clear benefit demonstrated [34–37] (Table  2). 
Similarly, aerobic exercise performance appears to remain 
unchanged following the administration of inhaled LABA 
[38, 39]. Over the past decade, multiple systematic reviews 
have concluded that inhaled β-2 agonists yield limited ergo-
genic benefit [24, 40, 41]; however, it is important to note 
that inhaled combination therapy (i.e. salbutamol, formo-
terol and salmeterol) (each within permitted doses) has been 
reported to improve sprint performance and maximal volun-
tary contraction [42]. To date, studies investigating inhaled 
corticosteroids at therapeutic doses have failed to show any 
improvement in exercise performance [43].
3.2  Inhaled/Oral β‑2 Agonists and Corticosteroids 
Requiring a TUE
Several studies investigating high-dose terbutaline have 
shown improvements (2–8%) in peak and average sprint 
power in trained cyclists [44, 45], as well as meaningful 
Table 2  Asthma medications and the prohibited list (2019)—status and impact on sports performance
Asthma medication Prohibited list status Impact on sports performance
β-2 agonists
 Short-acting β-2 agonists
  Salbutamol (excluding inhaled)
  Reproterol
  Terbutaline
Prohibited (all selective and non-selective  
β-2 agonists, including all optical isomers)
Increased strength and sprint power following acute and 
chronic administration [44–47, 51–53]
Improvement in submaximal endurance performance 
[50]
 Long-acting β-2 agonists
  Salmeterol (excluding inhaled)
  Formoterol (excluding inhaled)
  Indacaterol
  Olodaterol
  Tulobuterol
  Vilanterol
Prohibited (all selective and non-selective β-2 agonists, 
including all optical isomers)
No data available
 Other (intermediate acting)
  Fenoterol
  Higenamine
  Procaterol
Prohibited (all selective and non-selective  
β-2 agonists, including all optical isomers)
No data available
Inhaled salbutamol Permitted (maximum 1600 µg over 24 h in divided doses 
not to exceed 800 µg over 12 h)
No evidence to support improvement in aerobic capacity 
[34] or endurance performance [35–39]
Inhaled formoterol Permitted (maximum delivered dose of 54 µg over 24 h) Improved sprint performance [42]
Inhaled salmeterol Permitted (maximum 200 µg over 24 h)
Corticosteroids
  Betamethasone
  Budesonide
  Cortisone
  Deflazacort
Prohibited in-competition only (systemic administra-
tion [i.e. oral, intravenous, intramuscular and rectal] of 
corticosteroids)
Improved time to exhaustion at sub-maximal intensities 
(~ 70% aerobic capacity) following acute [54, 55] and 
short-term administration [56–58]
  Dexamethasone
  Fluticasone
  Hydrocortisone
  Methylprednisolone
  Prednisolone
  Prednisone
  Triamcinolone
Permitted at all times (inhaled administration of corti-
costeroids)
No impact on endurance performance [43]
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improvements in time to exhaustion at near maximal 
power outputs when combined with an inhaled corticos-
teroid [46]. Furthermore, daily terbutaline administration 
has been shown to elicit a significant increase in skeletal 
muscle growth in healthy males irrespective of a concur-
rent resistance exercise programme [47]. On the contrary, 
chronic use of terbutaline has been reported to impair skel-
etal muscle adaption following high-intensity training [48]. 
Despite this, establishing a urine threshold for athletes who 
acquire a TUE for terbutaline has been proposed to reduce 
supra-therapeutic dosing and the potential for performance 
enhancement [49]. The short-term oral administration of 
salbutamol has been shown to significantly improve sub-
maximal (~ 70–80% maximal oxygen uptake [VO2max]) 
time to exhaustion [50], with improvements in strength and 
power also noted [51, 52]. Furthermore, oral salbutamol has 
recently been shown to increase protein turnover rates in 
skeletal muscle following resistance exercise [53].
The acute administration of an oral corticosteroid has 
been previously shown to improve prolonged sub-maximal 
exercise performance in trained cyclists [54, 55]. Improve-
ments in time to exhaustion at sub-maximal exercise inten-
sities (70–75% VO2max) have also been observed following 
systemic corticosteroid administration [56–58]. It has been 
proposed that oral corticosteroids may improve exercise 
performance from both a psychological and physiological 
perspective by inducing the perception of euphoria [59] and 
increasing fat oxidation to meet energy requirements during 
exercise [60]. Oral corticosteroids have also been associated 
with increased lipolysis [61], resulting in changes to body 
composition; the latter being considered desirable for endur-
ance-based athletes (i.e. increased power: weight ratio) [62]. 
Finally, a blunted pro-inflammatory response post-exercise 
has also been observed following oral corticosteroid admin-
istration [55], which in turn may translate to enhanced recov-
ery between repeated exercise bouts (e.g. tennis tournaments 
or multiple-stage cycling events etc.).
4  Asthma Medication Use in Athletes—
Treatment or Permitted Doping?
In recent major sporting competitions such as the Olympic 
Games, World and European Championships and Common-
wealth Games, asthma has been noted as a common justifi-
cation for the use of prohibited substances by elite athletes, 
illustrated by the leaking of TUE information and medica-
tion use by the Russian cyber espionage group ‘Fancy Bears’ 
[63]. Although there was no suggestion of wrong-doing on 
the part of the athletes whose data was leaked, the omni-
present use of asthma medication by high-profile athletes 
questions the legitimacy of the anti-doping system in this 
setting [33].
Fundamentally, the purpose of the Code is not to restrict 
the use of required medication in athletes with asthma and 
prevent them from becoming elite competitors, however 
abuse of this system is both undesirable and certainly unethi-
cal. Media headlines covering high-profile athletes’ use of 
asthma medication may encourage the misuse of inhaler 
therapy amongst sub-elite or recreational-level athletes 
seeking a competitive advantage. On the contrary, the nega-
tive stigma surrounding asthma medication may actually act 
to deter an athlete from disclosing their diagnosis and/or 
refrain from using prescribed medication due to fear of being 
labelled a cheat. Taken together, these behaviours may be 
detrimental to the overall health and well-being of athletes or 
individuals partaking in sport across all levels. Understand-
ing athlete (and associated support personnel) capability, 
opportunity and motivation with regards the current TUE 
system and use of asthma medication is a necessary first 
step to facilitate interventions and modifications to ensure 
global anti-doping policy and practice can be reviewed and 
effectively delivered in a supportive and progressive manner.
4.1  Capability (Knowledge and Understanding)
Under the Code and concept of ‘strict liability’, athletes are 
solely responsible for the substances detected in their bio-
logical system regardless of whether use is intentional or 
not [11]. Therefore, athletes need to be knowledgeable and 
comply with all applicable anti-doping rules and regulations 
[11]. However, recent studies have exposed partial knowl-
edge and understanding of the policies and rules that govern 
participation in sport [64], rendering athletes at increased 
risk of committing ADRVs. For example, in a study involv-
ing athletes from the UK, USA, Australia and Canada, the 
prohibited list status of substances found in over-the-counter 
medications was correctly identified in only 35% of cases 
presented [65]. This finding is notable as 66% of the survey 
respondents had been subject to in- or out-of-competition 
testing. This lack of capability to navigate the complex 
anti-doping landscape can be linked to athletes’ insufficient 
exposure to formal anti-doping education [64]. Compound-
ing this situation further, stigma attached to anti-doping 
information seeking within elite sporting organisations has 
previously been reported [66].
Athletes reporting breathing difficulty most often seek 
medical guidance from non-specialist (i.e. neither respira-
tory nor sports medicine) healthcare professionals to man-
age their medical condition [67, 68]. It is important that 
all clinicians are aware and remain up to date with asthma 
guideline reports [9] given the global prevalence of the con-
dition, but specifically to ensure diagnosis is robust [69]. 
Over the past two decades, a wealth of published research 
has supported the concept that asthma is frequently mis-
diagnosed (i.e. over- and under-detected) in both elite and 
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recreational athletes [8, 70]. Despite recognition of the 
disconnect between self-report respiratory symptoms and 
objective evidence of asthma [71], a study by Hull et al. 
found that approximately one-quarter of primary care clini-
cians in the UK initiate treatment based on clinical history 
alone [68]. Although objective testing is often requested, 
test selection is typically sub-optimal for the assessment of 
the breathless athlete (e.g. baseline spirometry and/or peak 
expiratory flow) [68]. To date, the most appropriate diagnos-
tic test and/or criteria employed to detect asthma in athletes 
remains debated [72–74]; however, it has been recognised 
for some time that (a form of) bronchoprovocation challenge 
is required to support a diagnosis in the absence of baseline 
airflow obstruction with reversibility (Table 1). In support 
of this concept, and pertinent to anti-doping, a retrospective 
analysis in elite Portuguese athletes reported that the number 
of TUE applications for asthma medication decreased by 
over half (51%) between 2008 and 2009 following a man-
dated requirement to objectively document asthma [75]. 
Despite these findings, the diagnostic test currently endorsed 
by the IOC-MC (i.e. indirect bronchoprovocation via eucap-
nic voluntary hyperpnoea) [76] remains under-utilised and 
largely overlooked [68].
For clinicians prescribing asthma medication, an appre-
ciation and understanding of evidence-based treatment strat-
egies to optimise management remains a priority. However, 
in the same study by Hull et al. it was also reported that 
two-thirds of clinicians were unsure of the medications a 
competitive athlete is legally permitted to use following a 
diagnosis [68]. The annual updating of the prohibited list 
only adds to the challenges faced by clinicians when pre-
scribing medications to athletes competing under the Code. 
The lack of referring for specialist testing and knowledge of 
the Code is likely attributed to (a) the challenges of dissemi-
nating research to the relevant wider audience (e.g. sports 
physicians), (b) translation of findings into clinical practice, 
(c) limited access to appropriate diagnostic methods and (d) 
cost of referral to centres offering specialist assessment.
Taken together, the capability of athletes and clinicians 
(defined as athlete support personnel under the Code) to 
comply with current rules and regulations appears compro-
mised, increasing the potential to commit an ADRV [67]. 
To support athletes and the medical profession, tailored and 
targeted education programmes for clinicians therefore need 
to be developed and delivered to help rectify this situation.
4.2  Opportunity (Environment and Resources)
To address the concern surrounding clinician capability 
in the future, increasing the number of referrals to sports 
medicine practitioners and/or respiratory specialists (e.g. 
technicians and physiologists) with expertise in the diagno-
sis and management of breathing disorders in athletes may 
ensure optimal diagnostic methods and test interpretation. 
To ensure this happens, referral for specialist services must 
be easily available and promoted widely across the sports 
medicine community. If specialist services are not accessed, 
unnecessary inhaler therapy or the illegitimate prescription 
of asthma medication may be afforded to athletes. This is 
concerning given that the adverse health implications of 
unnecessary chronic SABA administration have been rec-
ognised for some time [31].
In some environments, the physical access to healthcare 
professionals willing to undermine the system by authorising 
a TUE for a fictional illness (e.g. asthma or musculoskel-
etal injury) has been reported [77]. For example, Lentillon-
Kaestner and Carstairs previously documented premedi-
tated misuse of therapeutic substances in a study involving 
young elite cyclists, with one rider admitting “If we want 
to take banned substances legally, we can. You just need to 
know a doctor who provides the therapeutic use exemption 
rather easily” [77]. Furthermore, in a similar study of Swiss 
National cyclists, another stated “All the riders I know, they 
all have tried cortisone. […]. Yes, they take therapeutic use 
exemptions (TUEs).[…].They play with the rules. It depends 
what you mean by doping but everyone I know, they do 
that” [78].
4.3  Opportunity (Social Influences)
Influenced by the dopogenic environment, the way ath-
letes, their support personnel and the public interpret TUE 
use is shaped by the prevailing social norms, including 
a distrust in competitors’ abuse and/or authorities’ man-
agement of the system [16, 64]. For example, amongst a 
sample of elite Danish athletes, the perception of over half 
surveyed was that fellow athletes had been granted a TUE 
without the clinical requirement, with many using higher 
doses of prescribed medication than required [16]. Simi-
larly, in a cohort of 260 elite athletes from four different 
sports federations (IAAF: athletics, FIBA: basketball, FIS: 
skiing, FIVB: volleyball), approximately half considered 
it unfair that athletes were granted permission to use an 
otherwise prohibited substance; with one athlete reporting 
“asthma and other disabilities should never give right to 
those athletes using a TUE when competing in the same 
champs” [79]. Furthermore, a recent study by Bourdon 
and colleagues highlighted that nearly half of their elite 
athlete cohort (approximately 60% endurance athletes) 
suspected their peers may abuse the system and that fel-
low competitors had incorrectly received a TUE [80]. In 
other sports where doping has received significant atten-
tion (e.g. bodybuilding), research has shown that an athlete 
is more likely to misuse a substance if they believe, or 
directly observe, others abusing [81]. This likelihood can 
be explained by moral disengagement, a process whereby 
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an athlete justifies unethical behaviours because of per-
ceived extenuating circumstances. For example, they may 
justify unethical behaviour on the basis that their peers 
are abusing the TUE system and getting away with it and/
or consider it to be levelling the playing field. Processes 
such as moral disengagement offer a coping strategy for 
reducing cognitive dissonance that occurs from holding 
conflicting beliefs and values. Central to the effects of 
moral disengagement concerning the TUE system is the 
training and competition environment [81], most pertinent 
when applied to groups with high asthma prevalence (e.g. 
pool-based or winter sport athletes) [7].
This research brings to the forefront the social oppor-
tunity in which asthma medications and the TUE system 
are perceived to be a legitimised form of doping. In turn, 
this may provide athletes and support staff with motiva-
tion to engage in behaviours that go against the spirit of 
sport [11], and that have the potential to compromise ath-
lete health and well-being. Influential others might also 
provide the motivation for non-asthmatic athletes to use 
unnecessary asthma medication through the widespread 
perception that inhaled SABA improves sports perfor-
mance. As detailed, this perception is despite the fact that 
the (potentially detrimental) impact of asthma on exercise 
performance has yet to be fully substantiated [32], with the 
majority of research supporting the absence of ergogenic 
benefit for inhaled SABA (i.e. salbutamol) and LABA (i.e. 
formoterol and salmeterol) that do not currently require a 
TUE in asthmatic and non-asthmatic athletes.
4.4  Motivation (Beliefs About Consequences)
At the other end of the spectrum, it has been reported that 
athletes may avoid applying for a TUE despite therapeutic 
need [16, 80]. Whilst these athletes may have the capa-
bility to adhere to a prescribed treatment, the stigma of 
TUEs and asthma medication may negatively influence an 
athlete’s motivation to manage their condition therapeuti-
cally. This is concerning as the continuation of training 
and competition without appropriate treatment may lead 
to a deterioration in condition and possibly sporting per-
formance. In contrast, in recreational athletes, poor asthma 
control due to the non-adherence to medication may deter 
physical activity and exercise engagement but may also 
have more serious consequences, particularly in athletes 
with severe or uncontrolled asthma (i.e. exacerbation and 
heightened risk of mortality). Increasing the transparency 
of medication use and the TUE process may be an impor-
tant intervention to address some of the issues raised. The 
rights of athletes concerning their personal data and medi-
cal information must also be balanced against the effects 
that public disclosure of all medication use and granted 
TUEs may have on perceptions of cheating within the ath-
lete community [82].
5  Asthma in Athletes—A Call to Action
This narrative review provides the first theory-informed 
critical appraisal of anti-doping policy as it applies to 
asthma management, medication use and sports perfor-
mance. Applying the COM-B model is a theoretical start-
ing point to understand behaviour concerning asthma 
medication use in sport and we offer this important over-
view to drive a ‘call to action’ concerning future research 
priorities (Fig. 1). To date, there remains limited research 
focusing on athlete knowledge and perceptions of doping 
and TUEs specific to asthma. It is probable that both ath-
letes and clinicians have inadequate knowledge of current 
anti-doping policy regarding asthma medication, which 
heightens the risk of receiving AAF and/or committing 
an ADRV.
The reliance on clinicians to provide guidance to 
athletes presenting with respiratory symptoms is also 
concerning as there appears to be a disconnect between 
research-informed evidence and current practice. The 
challenges clinicians face securing a robust diagnosis only 
furthers the negative stigma towards the use of inhaler 
therapy in athletes. Although several objective methods of 
assessment (each with a unique diagnostic methodology) 
are currently accepted, establishing consensus regard-
ing the ‘gold-standard’ approach to diagnosis (with clear 
objective criteria), and overcoming challenges accessing 
centres specialising in athlete respiratory health is nec-
essary to optimise the care afforded to athletes with and 
without asthma.
To fully understand and recognise the complexity of 
the dopogenic environment in this setting, it is necessary 
to qualitatively examine athlete motivation to use asthma 
medication and perceptions and understanding of asthma 
TUEs in sport. Moreover, the true impact of asthma and 
associated medication on sports performance remains 
to be fully determined. Until this point, it is likely that 
the negative stigma associated with inhaler therapy will 
remain. Although untested in the context of TUEs, the use 
of the COM-B model provides foundations for interven-
tion development (e.g. education programmes and envi-
ronmental restructuring) that can target the salient barriers 
of Code compliance and reduce the potential for ADRVs. 
Moving forward, developments in policy and practice have 
potential to change the behaviour of athletes and athlete 
support personnel, establish trust in the anti-doping sys-
tem, and in turn, alter the attitudes towards and percep-
tions of asthma medication use in sport.
 H. Allen et al.
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